Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2024
Prevalence and Prognosis of Mild Inflammatory Bowel Disease: A Population-based Cohort Study, 1997-2020.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jacobsen Henrik Albaek, Karachalia-Sandri Anastasia, Ebert Anthony C, Allin Kristine H, Ananthakrishnan Ashwin N, Agrawal Manasi, Ungaro Ryan C, Colombel Jean-Frederic, Larsen Lone, Jess Tine
Аннотация
BACKGROUND & AIMS: The inflammatory bowel diseases (IBDs), ulcerative colitis (UC) and Crohn's disease (CD), are heterogenous diseases ranging from mild to severe. We aimed to describe the prevalence and prognosis of mild IBD in an unselected population-based patient cohort.
METHODS: We identified all individuals diagnosed with IBD during 1997 to 2020 in North Denmark (n = 4607). Patients with mild disease, based on treatment history within the first year, were followed for progression to moderate-severe disease, based on a composite outcome of immunomodulators, biologic therapies, IBD-related hospitalization, and/or surgery. We used time-to-event analysis to calculate probabilities of progression based on IBD subtype, age, sex, and duration of mild IBD.
RESULTS: Among 2315 individuals with initial mild IBD, 24.5% with UC (n = 474) and 46% with CD (n = 174) progressed to moderate-severe disease during follow-up. Of the total IBD population, 52.3% of patients with UC and 86.8% with CD progressed during follow-up. Individuals <18 years at diagnosis were the most likely to progress. The 10-year probability of progressing to moderate-severe UC was 26% after 1 year with mild disease, 19% after 5 years, and 12% after 10 years. The probability of progressing to moderate-severe CD was 53% after 1 year with mild disease, 34% after 5 years, and 33% after 10 years.
CONCLUSIONS: Approximately one-fourth of individuals with mild UC within 1 year after diagnosis and one-half of those with mild CD progressed to moderate-severe disease over time. Young age at diagnosis increased the probability of progression, whereas increasing duration of mild disease decreased the probability.
METHODS: We identified all individuals diagnosed with IBD during 1997 to 2020 in North Denmark (n = 4607). Patients with mild disease, based on treatment history within the first year, were followed for progression to moderate-severe disease, based on a composite outcome of immunomodulators, biologic therapies, IBD-related hospitalization, and/or surgery. We used time-to-event analysis to calculate probabilities of progression based on IBD subtype, age, sex, and duration of mild IBD.
RESULTS: Among 2315 individuals with initial mild IBD, 24.5% with UC (n = 474) and 46% with CD (n = 174) progressed to moderate-severe disease during follow-up. Of the total IBD population, 52.3% of patients with UC and 86.8% with CD progressed during follow-up. Individuals <18 years at diagnosis were the most likely to progress. The 10-year probability of progressing to moderate-severe UC was 26% after 1 year with mild disease, 19% after 5 years, and 12% after 10 years. The probability of progressing to moderate-severe CD was 53% after 1 year with mild disease, 34% after 5 years, and 33% after 10 years.
CONCLUSIONS: Approximately one-fourth of individuals with mild UC within 1 year after diagnosis and one-half of those with mild CD progressed to moderate-severe disease over time. Young age at diagnosis increased the probability of progression, whereas increasing duration of mild disease decreased the probability.